The WSJ reported today that the FDA is still reviewing Moderna's EUA for 12-17 year olds in regards to myocarditis. This is regarding if Moderna has a higher myocarditis risk than Pfizer.
This seems more excessive caution than anything else. At yesterday's VRBPAC meeting the FDA data was presented on the myocarditis risk in young men showing that there is no significant difference in myocarditis risk between the two vaccines. But given recent moves by several Nordic countries to restrict Moderna's use in young people due to the risk, the FDA will take a closer look at the matter. The Nordic countries say that in unpublished data the Moderna vaccine had a higher myocarditis risk than Pfizer's.
I'll remind that the coronavirus itself causes significantly higher myocarditis risk than the vaccines, so young people should still get vaccinated as the benefits outweigh the costs. Myocarditis after Pfizer vaccination is an extremely rare phenomenon with 2.7 events per 100k after vaccination vs 11.0 events per 100k after coronavirus infection: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475